Mathilde Gourdel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mathilde Gourdel has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Alice Leon
Inserm, Université de Brest, EFS, UMR 1078, GGB, 29200 Brest, France
1 shared publication - Catherine Le Jossic-Corcos
Inserm U1078, Univ Brest, EFS, F-29200 Brest, France
1 shared publication - Claire Rollet
Inserm, Université de Brest, EFS, UMR 1078, GGB, 29200 Brest, France
1 shared publication - Cécile Voisset
Univ Brest, Inserm, EFS, UMR 1078, GGB, School of Medicine, 22 avenue Camille Desmoulins, Brest F-29200, France; Univ Brest, Inserm, IMT-A, UMR 1101, LaTIM, School of Medicine, 22 avenue Camille Desmoulins, Brest F-29200, France
1 shared publication - Frédéric Bihel
Laboratoire d’Innovation Thérapeutique, UMR 7200 CNRS, Université de Strasbourg
1 shared publication - Gaëlle Friocourt
Reference Centre of Rare Disease With Intellectual Disability and Multiple Disabilities , CHRU de Brest , Brest , France
1 shared publication
Latest Publications
- Open Access
- 17 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6769
Identification of 8-Hydroxyquinoline Derivatives That Decrease Cystathionine Beta Synthase (CBS) Activity
CBS encodes a pyridoxal 5′-phosphate-dependent enzyme that catalyses the condensation of homocysteine and serine to form cystathionine. Due to its implication in some cancers and in the cognitive pathophysiology of Down syndrome, the identification of pharmacological inhibitors of this enzyme is urgently required. However, thus far, attempts to identify such molecules have only led to the identification of compounds with low potency and limited selectivity. We consequently developed an original, yeast-based screening method that identified three FDA-approved drugs of the 8-hydroxyquinoline family: clioquinol, chloroxine and nitroxoline. These molecules reduce CBS enzymatic activity in different cellular models, proving that the molecular mechanisms involved in yeast phenotypic rescue are conserved in mammalian cells. A combination of genetic and chemical biology approaches also revealed the importance of copper and zinc intracellular levels in the regulation of CBS enzymatic activity—copper promoting CBS activity and zinc inhibiting its activity. Taken together, these results indicate that our effective screening approach identified three new potent CBS inhibitors and provides new findings for the regulation of CBS activity, which is crucial to develop new therapies for CBS-related human disorders.
- 17 June 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (12) , 6769
Open AccessIdentification of 8-Hydroxyquinoline Derivatives That Decrease Cystathionine Beta Synthase (CBS) Activity
CBS encodes a pyridoxal 5′-phosphate-dependent enzyme that catalyses the condensation of homocysteine and serine to form cystathionine. Due to its implication in some cancers and in the cognitive pathophysiology of Down syndrome, the identification of pharmacological inhibitors of this enzyme is urgently required. However, thus far, attempts to identify such molecules have only led to the identification of compounds with low potency and limited selectivity. We consequently developed an original, yeast-based screening method that identified three FDA-approved drugs of the 8-hydroxyquinoline family: clioquinol, chloroxine and nitroxoline. These molecules reduce CBS enzymatic activity in different cellular models, proving that the molecular mechanisms involved in yeast phenotypic rescue are conserved in mammalian cells. A combination of genetic and chemical biology approaches also revealed the importance of copper and zinc intracellular levels in the regulation of CBS enzymatic activity—copper promoting CBS activity and zinc inhibiting its activity. Taken together, these results indicate that our effective screening approach identified three new potent CBS inhibitors and provides new findings for the regulation of CBS activity, which is crucial to develop new therapies for CBS-related human disorders.